NCT02996773View on ClinicalTrials.gov

Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 29, 2016

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2025

Conditions

Acute Lymphoblastic LeukemiaAcute Myelogenous LeukemiaMyelodysplastic SyndromesChronic Myelogenous LeukemiaLymphoma,Non-HodgkinLymphoma, HodgkinLymphoma, FollicularMarginal Zone LymphomaLarge Cell LymphomaMantle-Cell LymphomaGray Zone LymphomaBurkitt LymphomaHigh Risk Undifferentiated Acute Leukemia

Interventions

DRUG

Bendamustine

After transplant, given intravenously on day +4 as part of Phase Ib.

DRUG

Cyclophosphamide

After transplant, given intravenously on day +3 as part of Phase 1b.

Trial Locations (1)

85724

The University of Arizona Cancer Center, Tucson

All Listed Sponsors

lead

University of Arizona

OTHER

NCT02996773 - Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | Biotech Hunter | Biotech Hunter